UroCCR Database: French Research Network for Kidney Cancer -UroCCR

Recruiting

• Conditions: Kidney Cancer

• Registration Number: NCT03293563
• Lead Sponsor: University Hospital, Bordeaux

Brief Summary

Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.

More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.

By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.

Detailed Description

The UroCCR project is a national kidney cancer registry and research network designed to address the specific challenges of renal cell carcinoma (RCC) management. While general cancer registries such as FRANCIM provide valuable surveillance data, most large-scale registries lack the depth of clinical, biological, and longitudinal follow-up information necessary to advance research and enable comprehensive analyses of kidney cancer outcomes. UroCCR was created in 2011 to meet this need.

With over 21,000 cases collected from 58 centres across France, UroCCR is now one of the largest national databases dedicated to kidney cancer worldwide. The registry captures detailed clinical parameters, treatments and outcomes, complemented by patient-reported measures and socioeconomic data. Because management practices within UroCCR follow the recommendations of the French Association of Urology (AFU), the dataset closely reflects real-world practice and provides a reliable basis for comparison with national and European guidelines. Moreover, patient data can be reused across numerous studies, allowing researchers to explore multiple scientific questions without requiring new enrolments for each project.

A distinctive strength of UroCCR is its integration of multiple research dimensions. Beyond clinical outcomes, it evaluates quality of life and the social and economic impact of kidney cancer. The registry is linked to annotated biobanking and national medico-administrative datasets, enabling translational studies and health services research. Additionally, UroCCR supports multiple ancillary studies, both retrospective analyses based on real-world data and prospective studies including randomised clinical trials or observational cohorts.

The project benefits from robust governance structures, ensuring standardised procedures, data quality, and ethical oversight. It has also received various national and international labels, recognising its methodological rigour and excellence in research infrastructure.

Digital innovations developed within the network, such as UroConnect® for perioperative monitoring and UroPredict machine learning models for recurrence and survival prediction, highlight its commitment to advancing care through new technologies.

At the national level, projects such as CARARE are developing personalised treatment strategies, including a molecular tumour board for non-clear cell RCC. Internationally, UroCCR is strengthening collaboration through partnerships with the European Association of Urology and the European Robotic Urology Section, contributing to harmonised data collection and large-scale multicentre research.

Ultimately, UroCCR functions as a dynamic research platform that unites clinicians, researchers, and patients around a shared infrastructure. By combining detailed clinical data with translational research, digital health tools, structured governance, recognised labels, and international partnerships, it aims to generate increasingly precise insights into RCC and to support the development of more effective, personalised treatment strategies in France and worldwide.

Study Timeline

• Study Start: 2011-12-01
• Study First Submitted: 2016-07-12
• Study First Submitted QC: 2017-09-20
• Study First Posted: 2017-09-26
• Status Verified: 2025-09
• Last Update Submitted: 2025-09-10
• Last Update Posted: 2025-09-17
• Primary Completion: 2040-12
• Study Completion: 2040-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30000

Inclusion Criteria

• Adult patient with kidney cancer
• Patient with no opposition to collection of its data for the study

Exclusion Criteria

none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Clinical scores

Secondary Outcome Measures

Name	Time	Method
Safety and efficacy of medical treatment on kidney tumor size evolution	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Imaging data: tumor size evolution
Dosage of creatininemia to assess the renal function after surgery	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Dosage of creatininemia
Progression of the tumor	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Imaging data: tumor location
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Medical or surgical complication rates with necessity for nephrectomy or re-exploration
Safety and efficacy of medical treatment on biological parameters	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Biological parameters
Dosage of MDRD GFR to assess the renal function after surgery	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Dosage of MDRD GFR

Trial Locations

Locations (58)

Hopital Universitaire de Bruxelles; 🇧🇪 Brussels, Belgium

CHU Angers; 🇫🇷 Angers, France

CHU Bordeaux; 🇫🇷 Bordeaux, France

Clinique TIVOLI-DUCOS; 🇫🇷 Bordeaux, France

Polyclinique Médipôle Saint-Roch_Cabestany; 🇫🇷 Cabestany, France

CHU Caen; 🇫🇷 Caen, France

CHU de Clermont-Ferrand; 🇫🇷 Clermont-Ferrand, France

Ch Sud Francilien; 🇫🇷 Corbeil-Essonnes, France

CHU Henri Mondor - APHP; 🇫🇷 Créteil, France

CHU de Dijon et CLCC Dijon; 🇫🇷 Dijon, France

Scroll for more (48 remaining)